Hypoxia-induced miR-181b enhances angiogenesis of retinoblastoma cells by targeting PDCD10 and GATA6

Oncology Reports

Volumn 33, Issue 6, 2015, Pages 2789-2796

  Xu, Xiaofang ^a   Ge, Shengfang ^a   Jia, Renbing ^a   Zhou, Yixiong ^a   Song, Xin ^a   Zhang, He ^a   Fan, Xianqun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiogenesis; Hypoxia; MiR 181b; Retinoblastoma

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; LYMPHOCYTE ANTIGEN; MICRORNA; MICRORNA 181B; PROGRAMMED CELL DEATH 10; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GATA 6; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; GATA6 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; MEMBRANE PROTEIN; MIRN181 MICRORNA, HUMAN; ONCOPROTEIN; PDCD10 PROTEIN, HUMAN;

ARTICLE; BIOINFORMATICS; CAPILLARY; CELL HYPOXIA; CONTROLLED STUDY; CYTOTOXICITY ASSAY; GATA6 GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HIF ALPHA GENE; HUMAN; HUMAN CELL; PDCD10 GENE; PREDICTION; PRIORITY JOURNAL; RETINOBLASTOMA; RETINOBLASTOMA CELL LINE; TUMOR VASCULARIZATION; WESTERN BLOTTING; BIOSYNTHESIS; ENDOTHELIUM CELL; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; CELL HYPOXIA; CELL LINE, TUMOR; ENDOTHELIAL CELLS; GATA6 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MEMBRANE PROTEINS; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA;

EID: 84928910766     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3900     Document Type: Article

References (34)

1. Kivelä T: The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 93: 1129-1131, 2009.
2. Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE and Hurwitz R: Retinoblastoma: review of current management. Oncologist 12: 1237-1246, 2007.
3. Chantada GL, Qaddoumi I, Canturk S, Khetan V, Ma Z, Kimani K, Yeniad B, Sultan I, Sitorus RS, Tacyildiz N, et al: Strategies to manage retinoblastoma in developing countries. Pediatr Blood Cancer 56: 341-348, 2011.
4. Canturk S, Qaddoumi I, Khetan V, Ma Z, Furmanchuk A, Antoneli CB, Sultan I, Kebudi R, Sharma T, Rodriguez-Galindo C, et al: Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol 94: 1432-1436, 2010.
5. Lee YJ, Lee JH, Moon JH and Park SY: Overcoming hypoxic resistance of tumor cells to TRAIL-induced apoptosis through melatonin. Int J Mol Sci 15: 11941-11956, 2014.
6. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
7. Gruber M and Simon MC: Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr Opin Hematol 13: 169-174, 2006.
8. Greco S and Martelli F: MicroRNAs in hypoxia response. Antioxid Redox Signal 21: 1164-1166, 2014.
9. McCarthy N: Hypoxia: micro changes. Nat Rev Cancer 14: 382-383, 2014.
10. Qin Q, Furong W and Baosheng L: Multiple functions of hypoxiaregulated miR-210 in cancer. J Exp Clin Cancer Res 33: 50, 2014.
11. Xu X, Jia R, Zhou Y, Song X, Wang J, Qian G, Ge S and Fan X: Microarray-based analysis: Identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol 38: 1385-1393, 2011.
12. Boutrid H, Jockovich ME, Murray TG, Piña Y, Feuer WJ, Lampidis TJ and Cebulla CM: Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci 49: 2799-2805, 2008.
13. Lan KL, Lan KH, Sheu ML, Chen MY, Shih YS, Hsu FC, Wang HM, Liu RS and Yen SH: Honokiol inhibits hypoxiainducible factor-1 pathway. Int J Radiat Biol 87: 579-590, 2011.
14. Tsai YP and Wu KJ: Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci 19: 102, 2012.
15. Voss MJ, Niggemann B, Zänker KS and Entschladen F: Tumour reactions to hypoxia. Curr Mol Med 10: 381-386, 2010.
16. Sudhakar J, Venkatesan N, Lakshmanan S, Khetan V, Krishnakumar S and Biswas J: Hypoxic tumor microenvironment in advanced retinoblastoma. Pediatr Blood Cancer 60: 1598-1601, 2013.
17. Bao B, Ali S, Ahmad A, Azmi AS, Li Y, Banerjee S, Kong D, Sethi S, Aboukameel A, Padhye SB, et al: Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One 7: e50165, 2012.
18. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, et al: A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867, 2007.
19. He L, He X, Lim LP, De Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134, 2007.
20. Sermeus A and Michiels C: Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2: e164, 2011.
21. Kluiver J, van den Berg A, De Jong D, Blokzijl T, Harms G, Bouwman E, Jacobs S, Poppema S and Kroesen BJ: Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene 26: 3769-3776, 2007.
22. Koritzinsky M, Magagnin MG, van den Beucken T, Seigneuric R, Savelkouls K, Dostie J, Pyronnet S, Kaufman RJ, Weppler SA, Voncken JW, et al: Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J 25: 1114-1125, 2006.
23. Zhao L and Ackerman SL: Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol 18: 444-452, 2006.
24. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M and Ju J: Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2: 113-121, 2006.
25. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3: 317-324, 2006.
26. Sun YC, Wang J, Guo CC, Sai K, Wang J, Chen FR, Yang QY, Chen YS, Wang J, To TS, et al: miR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer 14: 611, 2014.
27. Takiuchi D, Eguchi H, Nagano H, Iwagami Y, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, Marubashi S, Tanemura M, et al: Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology 13: 517-523, 2013.
28. He Y, Zhang H, Yu L, Gunel M, Boggon TJ, Chen H and Min W: Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development. Sci Signal 3: ra26, 2010.
29. Zhu Y, Wu Q, Xu JF, Miller D, Sandalcioglu IE, Zhang JM and Sure U: Differential angiogenesis function of CCM2 and CCM3 in cerebral cavernous malformations. Neurosurg Focus 29: E1, 2010.
30. Schleider E, Stahl S, Wüstehube J, Walter U, Fischer A and Felbor U: Evidence for anti-angiogenic and pro-survival functions of the cerebral cavernous malformation protein 3. Neurogenetics 12: 83-86, 2011.
31. You C, Sandalcioglu IE, Dammann P, Felbor U, Sure U and Zhu Y: Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations. J Cell Mol Med 17: 407-418, 2013.
32. Perlman H, Suzuki E, Simonson M, Smith RC and Walsh K: GATA-6 induces p21(Cip1) expression and G1 cell cycle arrest. J Biol Chem 273: 13713-13718, 1998.
33. Crawford SE, Qi C, Misra P, Stellmach V, Rao MS, Engel JD, Zhu Y and Reddy JK: Defects of the heart, eye, and megakaryocytes in peroxisome proliferator activator receptor-binding protein (PBP) null embryos implicate GATA family of transcription factors. J Biol Chem 277: 3585-3592, 2002.
34. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, et al: Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480, 2009.